Survey reveals persistent cancer medication shortages across major US health centers

The short version

• A survey of 34 cancer centers found that all participating facilities are currently experiencing shortages of at least one medication.[STAT]
• Over 20% of centers face deficits of five or more drugs, while a majority report disruption to clinical trials.[STAT]
• Two-thirds of facilities report patient treatment delays due to repeating prior authorization procedures with insurers.[STAT]
• Most centers manage care by limiting existing inventory, reducing waste, and using minimum recommended doses.[STAT]

Key facts

• The National Comprehensive Cancer Network surveyed 34 leading treatment facilities.[STAT]
• Every surveyed center reported experiencing a shortage of at least one cancer medicine, with more than 20% lacking five or more medications.[STAT]
• Two-thirds of the surveyed centers reported treatment delays caused by the need to obtain new prior authorizations from insurance providers.[STAT]
• A majority of the centers reported that clinical trials have been disrupted due to drug shortages.[STAT]
• Sixty-one percent of centers maintain patient care amid shortages by minimizing waste, limiting inventory usage, and providing the minimum suggested dose.[STAT]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• STAT+: Cancer medicines remain in short supply across the U.S., survey findsSTAT metered